A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Public ClinicalTrials.gov record NCT05577715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Study identification
- NCT ID
- NCT05577715
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2022 (Actual)
- Primary completion
- Aug 12, 2024 (Actual)
- Completion
- Aug 12, 2024 (Actual)
- Last update posted
- Sep 4, 2025
2022 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0007 | Orange | California | 92868-3201 | — |
| Local Institution - 0035 | Lone Tree | Colorado | 80124 | — |
| Local Institution - 0043 | Clermont | Florida | 34711-6699 | — |
| Local Institution - 0010 | Orange City | Florida | 32763-8316 | — |
| Local Institution - 0001 | Marietta | Georgia | 30060 | — |
| Local Institution - 0005 | Louisville | Kentucky | 40241-2832 | — |
| Local Institution - 0044 | Silver Spring | Maryland | 20904-7917 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202-2608 | — |
| Local Institution - 0002 | Kansas City | Missouri | 64132 | — |
| Local Institution - 0011 | Charlotte | North Carolina | 28207 | — |
| Local Institution - 0034 | Arlington | Texas | 76012-2510 | — |
| Local Institution - 0045 | Flower Mound | Texas | 75028-1713 | — |
| Local Institution - 0033 | Fairfax | Virginia | 22031-4629 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05577715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05577715 live on ClinicalTrials.gov.